Vaccinogen Announces SEC Clearance of Form 10 Registration Statement and Upgrade to OTC.QB Market

Vaccinogen, Inc.
OTC.QB: VGEN
Oct 17, 2013

SEC clearance of Vaccinogen's Form 10 registration statement is a significant milestone as it allowed us to upgrade to the OTC.QB marketplace tier, and the SEC's continuous reporting requirements provides transparency with the investment community.

FREDERICK, MD (October 17, 2013) - Vaccinogen, Inc.,
(OTC.QB: VGEN) a cancer vaccine company, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC") stating that the SEC had completed its review of the Company's Form 10 registration statement, effectively clearing comments with the SEC.  Upon receiving SEC clearance, the company immediately upgraded its marketplace tier on the OTC Link to OTC.QB status, effective October 16, 2013.

"SEC clearance of Vaccinogen's Form 10 registration statement is a significant milestone as it allowed us to upgrade to the OTC.QB marketplace tier, and the SEC's continuous reporting requirements provides transparency with the investment community," said Andrew L. Tussing, President of Vaccinogen. "We are excited that our common stock now trades on the OTC.QB Marketplace, which we believe will facilitate trading of our shares.  This is a critical step toward achieving our goal of trading on a major exchange such as NASDAQ or the NYSE."

About Vaccinogen, Inc.

Vaccinogen, Inc. is a cancer vaccine company that is clinically testing its OncoVAX® treatment which is designed to prevent the recurrence of colon cancer and potentially other solid tumors. It is a patented process that circumvents the extreme diversity of tumor cells by leveraging a patient's own live tumor cells to launch a broad immune response against colon cancer. The Company believes that OncoVAX, at an optimum dose and regimen, is the first colon cancer vaccine to demonstrate effectiveness in both preventing cancer recurrence after surgical resection of the primary tumor and addressing the diversity of cancer cells.  OncoVAX has completed five clinical studies, including a Phase III trial with the optimum dose and regimen.  The Company expects to begin a pivotal Phase IIIb trial under an FDA Special Protocol Assessment (SPA) classification in the fourth quarter of 2013. More information is available at www.vaccinogeninc.com

For further information:
David Carey/Tanner Kaufman
Lazar Partners Ltd.
212 867 1762
dcarey@lazarpartners.com
tkaufman@lazarpartners.com


print email rss